Drugs / Bictegravir/emtricitabine/tenofovir alafenamide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07532304 | May → Jul 2026 overdue | — | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bictegravir/emtricitabine/tenofovir alafenamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07532304 ↗ |
| Known as | BIC/FTC/TAF | “Participants will receive a single oral dose of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).” NCT07532304 ↗ |
| Route | Oral | “Participants will receive a single oral dose of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).” NCT07532304 ↗ |